Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2021 17:30 ET | Source: Molecular Templates, Inc.

Molecular Templates Provides Corporate Update and Outlines 2022 Milestones

Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402 Continued dose-finding with MT-5111 and MT-0169 Pipeline advancing with IND planned for CTLA-4 program in...
November 18, 2021 08:00 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402

AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
November 15, 2021 07:30 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results

AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
September 20, 2021 08:00 ET | Source: Molecular Templates, Inc.

Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

AUSTIN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
August 12, 2021 16:30 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results

AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
July 09, 2021 08:00 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors

AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
July 06, 2021 08:00 ET | Source: Molecular Templates, Inc.

Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
May 13, 2021 16:30 ET | Source: Molecular Templates, Inc.

Molecular Templates, Inc. Reports First Quarter 2021 Financial Results

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
April 12, 2021 07:00 ET | Source: Molecular Templates, Inc.

Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting I

AUSTIN, Texas, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
April 05, 2021 07:00 ET | Source: Molecular Templates, Inc.

Molecular Templates to Prioritize Next-Generation ETB Candidates

Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma Development of First-Generation ETB MT-3724 Has Been Discontinued,...